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Abstract
Generation of gain-of-function transgenic mice by targeting the Rosa26 locus has been established as an alternative to
classical transgenic mice produced by pronuclear microinjection. However, targeting transgenes to the endogenous Rosa26
promoter results in moderate ubiquitous expression and is not suitable for high expression levels. Therefore, we now
generated a modified Rosa26 (modRosa26) locus that combines efficient targeted transgenesis using recombinase-
mediated cassette exchange (RMCE) by Flipase (Flp-RMCE) or Cre recombinase (Cre-RMCE) with transgene expression from
exogenous promoters. We silenced the endogenous Rosa26 promoter and characterized several ubiquitous (pCAG, EF1a
and CMV) and tissue-specific (VeCad, aSMA) promoters in the modRosa26 locus in vivo. We demonstrate that the ubiquitous
pCAG promoter in the modRosa26 locus now offers high transgene expression. While tissue-specific promoters were all
active in their cognate tissues they additionally led to rare ectopic expression. To achieve high expression levels in a tissue-
specific manner, we therefore combined Flp-RMCE for rapid ES cell targeting, the pCAG promoter for high transgene levels
and Cre/LoxP conditional transgene activation using well-characterized Cre lines. Using this approach we generated a Cre/
LoxP-inducible reporter mouse line with high EGFP expression levels that enables cell tracing in live cells. A second reporter
line expressing luciferase permits efficient monitoring of Cre activity in live animals. Thus, targeting the modRosa26 locus by
RMCE minimizes the effort required to target ES cells and generates a tool for the use exogenous promoters in combination
with single-copy transgenes for predictable expression in mice.
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Introduction
Sequencing the genome of humans and rodents has provided an
immense set of uncharacterized genes, and within the past decades
several genetic approaches have been taken in order to address
their function. Embryonic stem (ES) cells [1] are pluripotent cells
[2,3] that have served as a powerful tool to study gene functions in
vitro and to generate knockout mice via homologous recombination
[4]. In order to complement data gained from loss-of-function
approaches, in vivo gain-of-function experiments have been carried
out by generating mice overexpressing a gene of interest. Gain-of-
function mouse models have been mainly generated by pronuclear
microinjection [5] and random integration of the transgene into
the genome. This quite often results in variable copy numbers,
unpredictable expression profiles and sometimes gene silencing
effects, therefore requiring extensive characterization of several
independent transgenic lines [6]. Thus, insertional mutagenesis
and the positional influence of endogenous genes and regulatory
elements often lead to misinterpretation of the phenotypes
observed [7,8,9]. Targeting a single-copy transgene to a specific
and well-defined locus can minimize these problems and provide a
predictable and reproducible expression profile.
The Rosa26 locus has beenused to drive ubiquitous geneexpression
from the Rosa26 promoter [10]. This locus offers an open chromatin
configuration in all tissues and disruption of the Rosa26 gene produces
no overt phenotype, which made it one of the most commonly used
genetic loci for targeted transgenesis [10,11]. However, targeting
transgenes to the endogenous Rosa26 promoter results only in
moderate ubiquitous expression and is not suitable for high expression
levels [12,13,14]. In contrast, targeting transgenes into the bactin locus
yields high transgene expression levels but causes problems because
heterozygous b-actin deletion produces phenotypes [15,16]. Exogenous
promoters targeted to the Rosa26 locus could allow high ubiquitous
transgene expression or even tissue-specific expression. The chicken
b-actin (pCAG) promoter targeted to the Rosa26 locus allows much
higher transgene expression in vivo [14]. Whether other strong and
ubiquitous promoters or tissue-specific promoters retain their
functional properties in the Rosa26 locus is unknown.
Recent studies suggest that the Rosa26 promoter can influence
transgene expression mediated by exogenous promoters inserted at
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in the Rosa26 locus suffers from mosaic transgene expression in
multiple organs [14]. Insulator sequences have been successfully
introduced into the murine hypoxanthine phosphoribosyltrans-
ferase (HPRT) locus [18] in order to shield inserted transgenes
from the influence of the HPRT promoter [19], and in this case
tissue-specific promoters have been shown to retain their
specificity [20]. This allows for tissue-specific transgene expres-
sion using specific promoters (e.g. to generate Cre lines).
However, the HPRT locus is on the X chromosome which
results in random inactivation of the inserted transgene in female
mice [19,20]. Thus, it would be desirable to modify the Rosa26
locus to minimize the influence of the Rosa26 promoter on
transgenes targeted to this locus.
Targeting the Rosa26 locus and other loci was mainly achieved
by homologous recombination in ES cells and therefore required
time-consuming and extensive screening of hundreds of ES cell
clones [10,11,12,13]. In contrast, recombinase-mediated cassette
exchange (RMCE) using heterospecific recognition targets allows
for very efficient and rapid targeted transgenesis in previously
modified ES cells [15,21]. RMCE of transgenes with exogenous
promoter into a modified Rosa26 locus that contains a shielded
integration site would therefore be an ideal tool for rapid genera-
tion of transgenic mice.
Here we report the generation of two ES cell lines with modified
Rosa26 loci that allow for either Cre/LoxP (modRosa26
LoxP ES
cells)- or Flp/FRT (modRosa26
FRT ES cells)-mediated RMCE.
We shielded the integration site with a Stop sequence to facilitate
the use of exogenous promoters. Using this system, several
ubiquitous and tissue-specific promoters were tested in vivo for
their utility when targeted to the modRosa26 locus. The methods
presented here not only minimize the time required for successful
targeting of the Rosa26 locus, but also demonstrate that the
modified Rosa26 loci, in combination with exogenous promoters,
represent versatile and validated tools for the generation of
transgenic mouse models.
Materials and Methods
Statement on Animal Welfare
All experiments were carried out in accordance with authori-
zation guidelines for the care and use of laboratory animals.
Studies described in this report were performed according to
Novartis animal license numbers 1022, 1331, 1943 and 2116.
Cell culture
Mouse BALB/c-I cells [22] were cultured in ES cell medium
[DMEM medium (Gibco) containing 15% fetal calf serum,
20 mM HEPES, 0.1 mM b-mercaptoethanol and 50 mg/ml
penicillin/streptomycin) and 1,000 U/ml leukemia inhibitory
factor on gelatin-coated culture dishes on mitomycin C-treated
embryonic mouse fibroblasts. Neural stem cell cultures were
prepared and maintained as previously described [23]. Briefly,
telencephali were dissected from E14.5 mR26CS-EGFP/Nestin-
Cre and mR26CS-EGFP control mice, the meninges were
removed and the tissue was triturated in neurosphere medium
consisting of DMEM/F12 (1:1), 0.2 mg/ml L-glutamine, 1%
penicillin/streptomycin, 2% B27, 2 mg/ml heparin, 20 ng/ml
EGF and 10 ng/ml FGF2. Neurospheres were split after 5–6 days
and plated on coverslips coated with 15 mg/ml poly-L-ornithine
and 40 mg/ml laminin at a density of 200,000 cells/cm
2. The
dispersed cultures were differentiated in neurosphere medium
without FGF2, EGF and heparin and fixed with 4% paraformal-
dehyde (PFA) after 5 days.
Generation of the modR26
LoxP and modR26
FRT loci by
homologous recombination in BALB/c ES cells
The Rosa26 locus on chromosome 6 was targeted in BALB/c-I
(hereafter BALB/c ) ES cells by homologous recombination between
exons 1 and 2 of the Rosa26 gene [11]. The Rosa26 homologous
recombination targeting plasmid was constructed by amplifying the
recombination arms using Rosa26 genomic sequences as a template
(kind gift of U. Mu ¨ller, FMI Basel, Switzerland). A 2.6-kb long arm
(primers: sense 59-AAAAGGTACCAATGTTCAAGCAGGACCA-
AA-39 and antisense 59-AAAAGGTACCAGATCTCTGAGTTTG-
AGCCC-39) and a 1.8-kb short arm (primers: sense 59-AAAAGCG-
GCCGCAAACAAATAGGATACTAGAA-39 and antisense 59-AA-
AAGAGCTCAGGCTTAAAGGCTAACCT-39) were amplified
and subcloned into a pBSIIKS+ plasmid. A synthetic Stop cassette
[24] as well as an SV40 promoter-hygromycin selection cassette
flanked with heterospecific Lox511/LoxP sites [25] were cloned in
between the 59and 39 Rosa26 homology arms resulting in the Rosa26
homologous recombination plasmid (HR modR26
LoxP). A second
Rosa26 homologous recombination plasmid (HR modR26
FRT)w a s
constructed as described above, but heterospecific FRT3/FRT
wildtype (wt) sites [26] flanked the SV40 promoter-hygromycin
selection cassette. BALB/c mouse ES cell culture was performed with
primary X-ray-inactivated embryonic fibroblasts derived from DR4
mice. ES cells were transfected by electroporation using 20 mgo fS a c I -
digested HR modR26
LoxP or HR modR26
FRT plasmid. Transfected
ES cells were selected for hygromycin resistance using 0.1 mg/ml
hygromycin (Roche #843 555). Ten days after transfection, 500 Hyg-
resistant ES cell clones were isolated and analyzed by PCR for
homologous recombination. For this purpose, ES cell DNA was
extracted in 50 ml of lysis buffer [10 mM Tris-HCl (pH 8.0), 0.05%
SDS, 50 mg/ml proteinase K], and diagnostic PCR was performed
using 1 ml of crude ES cell extract in a total volume of 25 mlu s i n gt h e
Qiagen Taq PCR Master Mix (primers: sense 59-CGACTTGAG-
TTGCCTCAAGA-39 and antisense 59-TGGCTGAACTGAGCG-
AACA-39). Then, 1 ml of the first reaction was used as a template for a
nested PCR (primers: sense 59-GGCAGGAAGCACTTGCTCTC-
39and antisense 59-ACAACAACGGCGGCTACAAC-39), yielding a
2.1-kb fragment in positive clones (data not shown). Positive
recombination events were further validated by Southern blot analysis
(data not shown). We only observed 1% efficiency when homologous
recombination was used to target the Rosa26 locus in BALB/c ES
c e l l s ,w h i c hi si nc o n t r a s tt or e p o r t sw h i c hs h o wm u c hh i g h e r
recombination efficiency in 129 ES cells [14].
Construction of the RMCE plasmids
Cre-RMCE plasmids. The Cre-RMCE plasmid backbone
was based on a pCE-tkNeo plasmid containing heterospecific
Lox511 and LoxP sites and a herpes simplex virus thymidine
kinase promoter-driven neomycin resistance gene (NeoR) cassette
[16]. To enable tetracycline-regulated gene expression from the
cytomegalovirus (CMV) promoter, a SmaI/XhoI TRE fragment
was isolated from the TRE2-puro plasmid (Clontech) and cloned
in an AflIII-blunted site of pEGFP-N-1 (Invitrogen) to create
pEGFP-N1-TRE. The resulting TRE-CMV-EGFP AflIII/AflII
fragment was blunted before ligation into the SmaI-digested pCE-
tkNeo plasmid, yielding the pCE-tkNeo-TRE-CMV-EGFP vector.
To allow excision of the NeoR cassette, it was replaced by an
FRT-flanked NeoR cassette in the EcoRV-digested pCE-tkNeo-
TRE-CMV-EGFP plasmid to finally generate the mR26-CMV-
EGFP Cre-RMCE plasmid. Next, the mR26-EF1a-EGFP plasmid
was generated by isolating a 1,251-bp elongation factor 1a (EF1a)
promoter fragment from the pNAS-092 plasmid [27] which was
then ligated into the BglII/NsiI-digested mR26-CMV-EGFP Cre-
RMCE plasmid. In addition the pCAG promoter [28] was first
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digested pEGFP-N1-TRE plasmid and subsequently into the
NdeI/XmaI-digested mR26-CMV-EGFP, yielding the mR26-
pCAG-EGFP plasmid.
Flp-RMCE plasmids. To clone the VeCad-Cre-Flp-RMCE
plasmid, the mouse vascular endothelial cadherin promoter
(VeCad) promoter [29] was amplified by Solvias AG such that
the amplification product contains XbaI restriction sites at both
ends. The VeCad promoter fragment was subcloned into NheI-
linearized Flp-RMCE1 plasmid. Flp-RMCE1 contained FRT3 and
FRTwt sites flanking a multiple cloning site and a herpes simplex
virus thymidine kinasepromoter-driven NeoR cassette as a group as
well as an ampicillin resistance cassette. In contrast to the Cre-
RMCE-based design, the NeoR cassette cannot be removed in the
Flp-RMCE-based design. Finally NLS-Cre [30] was amplified and
cloned into the NotI restriction site downstream of the VeCad
promoter, resulting in the VeCad-Cre-Flp-RMCE plasmid. The
aSMA-Cre-Flp-RMCE plasmid was cloned by amplifying the a-
smooth muscle actin (aSMA) promoter [31] while introducing NheI
restriction sites at both ends. The aSMA promoter fragment was
then cloned into the NheI-linearized Flp-RMCE. Finally NLS-Cre
was amplified and cloned into the NotI restriction site downstream
of the aSMA promoter, yielding the aSMA-Cre-Flp-RMCE
plasmid. The Flp-RMCE2 plasmid was based on Flp-RMCE1,
containing in addition the pCAG promoter [28] and a LoxP-
flanked Stop cassette [24]. The mR26CS-EGFP plasmid was
constructed by cloning an AgeI/NotI-digested enhanced green
fluorescent protein (EGFP) fragment from pEGFP-N1 (Invitrogen)
into the AgeI/NotI-digested Flp-RMCE2. The mR26CS-Luc
plasmid was generated using the Flp-RMCE3 plasmid as a
backbone, which was identical to the Flp-RMCE2 plasmid but
used a different LoxP-flanked Stop cassette (Stop2) that is based on
the 39-UTR of the mouse albumin gene [32]. We introduced the
new Stop cassette to avoid possible recombination events that could
occur when using the same cassette twice. However, to date we
never observed such recombination event in any of our studies. The
luciferase was amplified while introducing AgeI/NotI sites and
cloned into the AgeI/NotI-digested Flp-RMCE3.
RMCE in modRosa26
LoxP and modRosa26
FRT ES cells
A total of 0.5610
6 ES cells were treated with Effectene (Qiagen,
Chatsworth, CA, USA) and cotransfected with 0.8 mg of pMC-Cre
and 0.2 mg of Cre-RMCE plasmid according to the manufactur-
er’s protocol and subsequently selected for G418 resistance. Cre-
mediated recombination into the modRosa26
LoxP locus was
confirmed by PCR and Southern hybridization (data not shown
and Figure 1C). DNA for PCR and Southern blot was isolated by
pelleting ES cells using centrifugation and digestion in lysis buffer
(ddH2O, 0.05% SDS, 1 mM TrisHCl and 25 mg/ml proteinase K)
overnight at 55uC. The 1:10 diluted digested samples were then
used for PCR, whereby the first PCR (primers: sense 59-AGCAGCC-
GATTGTCTGTTGT-39,a n t i s e n s e5 9-TGTGTGTATTCCTGG-
CTATCC-39) was used as a template for a nested PCR (primers: sense
59-TCATAGCCGAATAGCCTCTC-39,a n t i s e n s e5 9-TGATGTG-
TAGACCAGGCTGG-39) in order to amplify a 594-bp fragment
(data not shown). For Southern blot analysis, genomic DNA was
digested with BamHI overnight, run on a 1% agarose gel and blotted
on a nylon membrane (Hybond N+,A m e r s h a m ) .H y b r i d i z a t i o nw a s
performed overnight at 65uC using a 1.2-kb hybridization probe
derived from the NeoR gene labeled with
32P (Rediprime II Random
prime labeling kit, Amersham), detecting a 2.4-kb BamHI fragment in
mice with the targeted modR26
LoxP locus. After washing, the
membrane was exposed to a Kodak BioMax MS film. For detection
of Flp-mediated RMCE, ES were treated as described above and
cotransfected with 0.8 mg of pCAG-flpe [15] and 0.2 mgo ff l p - R M C E
plasmid. Flp-mediated recombination into the modRosa26
FRT locus
was confirmed by TaqMan PCR (sense primer 59-ATATCCGCG-
GTGGAGATCAA-39, antisense primer 59-TAGACCAGGCTGG-
GCTAAA-39,p r o b e5 9-VIC-CGGTACCAGATCTC-MGB-39)a n d
Southern blot analysis (data not shown).
Generation, breeding and genotyping of transgenic mice
ES cells with cassette exchange events in the modRosa26
LoxP or
modRosa26
FRT locus and preserved karyotypes were used for
blastocyst injection as described elsewhere [16]. Chimeric mice were
mated with BALB/c mice. Germline transmission was observed for
all lines targeted to both the modR26
LoxP (mR26-CMV-EGFP,
mR26-EF1a-EGFP, mR26-pCAG-EGFP) and the modRosa26
FRT
locus (mR26-VeCad-Cre, mR26-aSMA-Cre, mR26CS-EGFP and
mR26CS-LUC). Heterozygous transgenic mice with a targeted
modRosa26
LoxP locus were used for EGFP fluorescence and
immunohistochemistry analysis. Genotyping for micewith successful
Cre-RMCE targeting of the modRosa26
LoxP locus was performed
by TaqMan PCR. In brief, small tail biopsies were digested in
proteinase K-containing lysis buffer overnight at 55uC. The 1:10
diluted digested samples were then genotyped by TaqMan PCR for
NeoR (sense primer 59-GCCCGGTTCTTTTTGTCAAG-39,a n -
tisense primer 59-GCCTCGTCCTGCAGTTCATT-39 ,p r o b e5 9-
FAM-CCGACCTGTCCGGTGCCC-TAMRA-39)o rE G F P( s e n s e
primer 59-ACAGCTCGTCCATGCCGA-39, antisense primer 59-
TCACATGGTCCTGCTGGAGT-39,p r o b e5 9-FAM-TGATCCC-
GGCGGCGGTCA-TAMRA-39). Heterozygous transgenic mice
with the targeted modR26
FRT locus were crossed with CMV-Cre
[33], Nestin-Cre [34], Myf5-Cre [35] and Glast-CreER
T2 [36,37]
mice for conditional Cre-mediated transgene activation. Genotyping
was performed by TaqMan PCR for the Flp-RMCE-targeted
modRosa26
FRT locus (sense primer 59-ATATCCGCGGTGGAGA-
TCAA-39, antisense primer 59-TAGACCAGGCTGGGCTAAA-39,
probe 59-VIC-CGGTACCAGATCTC-MGB-39), Cre (sense primer
59-GCCGCGCGAGATATGG-39, antisense primer 59-GCCACC-
AGCTTGCATGATC-39,p r o b e5 9-FAM-CCGCGCTGGAGTT-
TCAATACCGG-TAMRA-39) and luciferase (sense primer 59-GA-
CGGAAAAAGAGATCGTGGAT-39, antisense primer 59-CAAC-
TCCTCCGCGCAACT-39,p r o b e5 9-FAM-CGCCAGTCAAGTA-
ACAACCGCGAAA-TAMRA-39). All mice with the targeted
modRosa26
LoxP or modRosa26
FRT locus were born at a normal
Mendelian ratio and showed no overt phenotype. All animals
had unrestricted access to water and food. Protocols, handling and
care of the mice conformed to the Swiss federal law for animal
protection.
FACS analysis and EGFP quantification
ES cell clones with EGFP driven by different promoters after
Cre-RMCE targeting to the modR26
LoxP locus were harvested by
trypsinization, and the EGFP fluorescence from 10
6 cells was
determined by FACS Analysis (BD FACScalibur). Mice were
euthanized with CO2, and selected organs (salivary glands, heart,
pancreas, liver, kidney, fat, muscle, brain and testis) were excised,
rinsed with ice-cold PBS and placed on ice. Whole-organ pictures
were taken at low magnification using a Zeiss Axiovert 25
binocular fluorescence microscope (Zeiss). Organ homogenates
were prepared in PBS containing protease inhibitors (Roche) and
subsequently analyzed for EGFP fluorescence using a 96-well
fluorescence reader (Wallac 1420 at 485 nm/535 nm, 1.0 s).
Background fluorescence levels for each organ were determined
using BALB/c wt littermates and subtracted from the relative
fluorescence values for each organ (n$5 mice per genotype).
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Mice were sacrificed by cervical dislocation, and organs were
removed. Samples for protein, DNA and RNA analysis were
immediately frozen at 280uC. Samples for histological examina-
tion were fixed overnight with 4% PFA in phosphate-buffered
saline (PBS) at 4uC and frozen in OCT (TissueTEK). Then, 10-
mm-thick cryostat sections were mounted, washed in PBS and
incubated for 1 h in blocking solution (2% BSA and 0.2% Triton X-
100 in PBS), followed by overnight incubation at 4uC in blocking
solutioncontainingprimaryantibodies,Alexa-594-conjugated wheat
germ agglutinin (W11262, Molecular Probes; 1:1,000) or biotiny-
lated Dolichos biflorus agglutinin (Vector Laboratories, Burlingame,
CA, USA; 1:100). Alternatively, mice were deeply anaesthetized by
injection of a ketamine/xylazine/flunitrazepam solution (150 mg,
Figure 1. Generation of mice with a modified Rosa26 locus (modRosa26
LoxP) and testing of different promoters. (A) Scheme depicting
the generation of the modRosa26
LoxP in ES cells. A Stop sequence and a HygR selection cassette flanked by heterospecific LoxP sites (Lox511 and
LoxP) were targeted to the Rosa26 locus between exons 1 and 2 by homologous recombination. After successful recombination, the Stop cassette is
located downstream of the endogenous Rosa26 promoter. (B) Cre-RMCE into the modRosa26
LoxP locus. In the Cre-RMCE targeting plasmid, a
promoter, EGFP and an FRT-flanked neomycin selection cassette (NeoR) were flanked by heterospecific LoxP sites (Lox511 and LoxP) as a group. Cre-
RMCE was used to replace the HygR in the modRosa26
LoxP ES cells with the Lox511/LoxP-flanked sequence in the RMCE targeting plasmid. A pCAG,
CMV or EF1a promoter driving EGFP was introduced. Insertion of EGFP without any promoter (NoP) controls for functional shielding of the
integration site from the endogenous Rosa26 promoter. Binding regions for TaqMan genotyping primers (1, 3) and probe (2), primers for checking
integration into the modRosa26
LoxP locus (4–7) and the Southern hybridization probe, as well as the BamHI sites used for Southern blot analysis are
indicated. (C) Southern blot analysis on genomic DNA-derived ES cell lines shows specific integration into the modRosa26
LoxP locus. A 2.4-kb BamHI
fragment was detected using a Neo probe. mR26-pCAG-EGFP, mR26-CMV-EGFP, mR26-EF1a-EGFP and mR26-NoP-EGFP ES cells show successful
targeting of the modRosa26
LoxP locus, without additional integrations at random sites. Wt ES cells show no signal. (D) Modified ES cells showing
strong EGFP fluorescence. The pCAG, EF1a and CMV promoters drive strong EGFP expression in the modRosa26
LoxP in vitro. ES cells without
promoter but with EGFP inserted into the modRosa26
LoxP locus do not show EGFP fluorescence, indicating functional shielding of the integration site
from the endogenous Rosa26 promoter. (E) FACS analysis in mR26-NoP-EGFP ES cells showed no EGFP fluorescence when compared to wt ES cells.
mR26-EF1a-EGFP ES cells showed the highest EGFP fluorescence, followed by mR26-pCAG-EGFP, ActB and mR26-CMV-EGFP ES cells.
doi:10.1371/journal.pone.0030011.g001
A Modified Rosa26 Locus for Mouse Model Generation
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e300117.5 and 0.6 mg/kg body weight, respectively) and perfused with ice-
cold 0.9% saline solution followed by ice-cold 4% PFA solution in
0.1 M phosphate buffer. Brains were post-fixed with 4% PFA
overnight, washed in phosphate buffer, cryoprotected in a 30%
sucrose solution in 0.1 M phosphate buffer for 48 h, embedded and
frozen in OCT (TissueTEK). Free-floating coronal sections (30 mm)
were collected in multi-well dishes and stored at 220uC in antifreeze
solution until use. For immunostaining, sections were incubated
overnight at 4uC with the primary antibody diluted in blocking
solution of 2% normal donkey serum (Jackson ImmunoResearch)
and 0.5% Triton X-100 in PBS. The primary antibodies used were
rabbit anti-hepatocyte nuclear factor 4a (HNF4a) (H-171, Santa
Cruz Biotechnology, Santa Cruz, CA, USA; 1:100), mouse anti-
NeuN (MAB377, Chemicon; 1:500), rabbit anti-GFAP (ZO334,
Dako; 1:1,000), mouse anti-NeuN (Sigma; 1:800), rabbit anti-BLBP
(Chemicon; 1:1,000), mouse anti-GFAP (Chemicon; 1:1,000) and
rabbit anti-MAP2 (Chemicon; 1:500). After rinsing in PBS, sections
were incubated in blocking solution containing secondary antibodies
for 1 h at room temperature. The secondary antibodies used were
Cy3-conjugated donkey anti-rabbit, Cy3-conjugated donkey anti-
mouse, Cy5-conjugated donkey anti-rabbit, Cy5-conjugated donkey
anti-mouse, Cy5-conjugated donkey anti-sheep and streptavidin-
Alexa 647 (Jackson ImmunoResearch, UK; 1:500). Immunofluores-
cence sections were imaged using a Leica DMI6000 fluorescence
microscope or a Zeiss LSM510 confocal microscope. For diamino-
benzidine (DAB) staining, tissue was fixed in 10% buffered formalin
for 48 h and embedded in paraffin using a standard procedure.
Then, 3-mm sections were cut using a microtome and rehydrated,
and endogenous peroxidase activity was quenched with 0.5% H2O2
in methanol for 20 min, followed by washing with Tris-buffered
saline containing 0.5 M Tris and 0.9% NaCl, pH 7.6 (TBS).
Sections were then blocked with 10% goat serum in TBS for 20 min
and incubated with rabbit anti-EGFP antibodies (589, MBL; 1:500)
in 1% goat serum containing TBS overnight at 4uC. Immunostain-
ing was completed using the Vectastain ABC Kit (PK-6101, Vector
Laboratories) according to the manual and followed by 15-min
incubation with DAB (Dako) and counterstaining with hematoxylin.
Sections were analyzed with an Axio ImagerZ1 microscope
equipped with an AxioCam MRc Rev3 color camera.
Luciferase reporter gene assay
Mice were deeply anesthetized with pentobarbital (10 mg/kg
body weight), and the fur was shaved. Firefly D-Luciferin (Caliper
Life Sciences) was dissolved in PBS then filtered, and 10 ml/kg
body weight was injected i.p. into the mice. Luminescence was
measured 10 min after Firefly D-Luciferin injection using a
Xenogen camera (Living Image 2.5, Caliper Life Sciences) and
Living Image Software. To determine luciferase activity in organ
homogenates, mice were sacrificed by cervical dislocation and
organs were removed and placed on ice. Organs were homoge-
nized by brief sonication in ice-cold PBS containing protease
inhibitors (Roche). Then, 100 ml per well was transferred into 96-
well plates, and 10 ml of Luciferin (Bright Glo Assay Reagent,
Promega) was added to each sample. Samples were measured
using a 96-well luminescence reader (Wallac 1420).
CreER
T2 induction by tamoxifen
In order to specifically recombine adult neural progenitors and
astrocytes in mR26CS-EGFP and mR26CS-N2ICD mice, we
used GLASTCreER
T2 mice [36,37]. Adult mice between 8 and 12
weeks of age were used for the experiments. Stock solutions of
tamoxifen (Sigma) were prepared at a concentration of 20 mg/ml
in corn oil (Sigma). Mice were injected i.p. with tamoxifen once
per day for 10 consecutive days at a dose of 2 mg/day. Animals
were sacrificed 21 days after the last injection, and the brains were
prepared for immunohistochemistry as described above.
Results
RMCE into the modRosa26
LoxP locus for rapid generation
of transgenic ES cells
To facilitate and accelerate gene targeting to a defined locus, we
modified the well-defined Rosa26 locus for fast, easy and specific
integration of various transgenic constructs in mouse BALB/c ES
cells. By means of homologous recombination, we introduced a
cassette that enables site-directed RMCE mediated by Cre
recombinase (Cre-RMCE) (Figure 1A). ES cells with a modified
Rosa26 locus harboring heterospecific LoxP sites (modRosa26
LoxP
ES cells) were then used for Cre-RMCE, resulting in very efficient
site-directed integration of the Lox511/LoxP-flanked sequence of
the Cre-RMCE plasmid into the modRosa26
LoxP locus (Figure 1B).
Recombination events were identified by a shift from hygromycin
resistance to G418 resistance and confirmed by PCR (data not
shown) and Southern blot analysis (Figure 1C). Site-directed Cre-
RMCE into the modRosa26
LoxP locus occurred in 9564% of all
G418-resistant/hygromycin-sensitive clones (n=5 independent
RMCEs). Therefore, we drastically minimized the time and effort
required to target transgenes to this locus when compared to other
homologous recombination strategies.
Comparison of different ubiquitous promoters in the
modRosa26
LoxP locus in vitro
For functional testing of transgene expression from the
modRosa26
LoxP locus using exogenous promoters, we introduced
three different ubiquitous promoters driving an EGFP reporter
gene by Cre-RMCE into modRosa26
LoxP ES cells. Since the
Rosa26 promoter offers only moderate expression levels [14], we
aimed to find a strong and ubiquitous promoter that can be used
in the modRosa26
LoxP locus for high-level transgene expression.
The promoters tested were the chicken b-actin promoter (pCAG)
[28], the elongation factor 1a promoter (EF1a) [38] and the
cytomegalovirus (CMV) promoter [39]. As a reference control we
used ES cells, that have EGFP targeted to the b-actin locus (ActB
ES cells) and have been shown to induce much higher expression
levels than the Rosa26 promoter [16]. BALB/c wt ES cells and ES
cells with EGFP targeted to the modRosa26
LoxP locus without any
promoter (mR26-NoP-EGFP) served as negative controls. Trans-
genic ES cells driving EGFP from the pCAG (mR26-pCAG-
EGFP), EF1a (mR26-EF1a-EGFP) or CMV (mR26-CMV-EGFP)
promoter showed strong EGFP fluorescence, comparable to
ACTB ES cells (Figure 1D). As in wt ES cells, no EGFP
fluorescence could be detected when no promoter was present
(modR26-NoP-EGFP) (Figure 1D). These results were confirmed
by FACS analysis for EGFP fluorescence intensity using these ES
cells. Wt and mR26-NoP-EGFP ES cells showed no EGFP
fluorescence, whereas mR26-EF1a-EGFP ES cells showed the
highest EGFP fluorescence, followed by ES cells with the pCAG or
CMV promoter (Figure 1E). The absence of EGFP fluorescence in
mR26-NoP-EGFP ES cells showed that the endogenous Rosa26
promoter was functionally silenced by the inserted Stop sequence.
Comparison of different ubiquitous promoters in the
modRosa26
LoxP locus in vivo
Since the CMV, EF1a and pCAG promoters proved to allow
high-level transgene expression in vitro when targeted to the
modRosa26
LoxP locus, we then tested their activity in this locus in
vivo. For this purpose, we generated transgenic mice using the
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EGFP ES cells. After blastocyst injection, highly chimeric offspring
were mated with BALB/c mice, and germline transmission was
observed for all lines generated within the first litter. All mR26-
pCAG-EGFP, mR26-EF1a-EGFP and mR26-CMV-EGFP mice
were born at a normal Mendelian ratio, were fertile and did show
any overt phenotype. Selected organs (salivary glands, heart,
pancreas, liver, kidney, fat, muscle, brain and testis) from 6- to 8-
week-old mice were analyzed for EGFP expression (Figure 2A).
EGFP fluorescence in organ homogenates was quantified, and the
fluorescence levels driven from the pCAG, EF1a and CMV
promoters were compared to those in ActB mice [16] (Figure 2B).
Since these mice express EGFP from the endogenous b-actin
locus, they offer high EGFP expression but the heterozygous loss
of b-actin results in an overt phenotype and homozygous loss of b-
actin is embryonically lethal [16]. Therefore we aimed to find a
promoter which offers a similarly high expression level in the
Rosa26 locus but does not have such disadvantages. Surprisingly,
mR26-CMV-EGFP mice did not show ubiquitous EGFP
expression in vivo, in contrast to the high EGFP expression seen
in undifferentiated mR26-CMV-EGFP ES cells in vitro. Relatively
high EGFP fluorescence was only found in testis, and some mosaic
staining was present in heart and pancreas (Figure 2A, 2B, data
not shown). The mR26-EF1a-EGFP mice showed moderate
EGFP fluorescence levels in all organs analyzed and strong levels
in testis, although all levels were lower than in ActB mice. In
contrast, mR26-pCAG-EGFP mice showed much higher levels of
EGFP fluorescence than ActB mice in most organs. Only in fat
tissue ActB mice showed higher EGFP fluorescence than mR26-
pCAG-EGFP mice, while liver and testis showed comparable
EGFP fluorescence levels. Heart, pancreas and muscle showed
extremely high EGFP fluorescence in mR26-pCAG-EGFP mice,
10 times higher than that seen in the same organs of ActB mice
(Figure 2B). Histological analysis using cryosections prepared from
muscle, brain and liver (Figure 2C) and other organs (kidney, lung
and heart; data not shown) of mR26-pCAG-EGFP mice showed
an overall higher level of EGFP fluorescence (visible without
EGFP antibody staining) than that seen in comparable sections
prepared from ActB mice. However, in liver sections from mR26-
pCAG-EGFP mice EGFP fluorescence was highly mosaic. While
many HNF4a-positive hepatocytes and Dolichos biflorus agglutinin-
positive bile ducts showed high EGFP fluorescence, some
hepatocytes were EGFP-negative (Figure 2C). In skeletal muscle
sections the EGFP fluorescence was extremely high in mR26-
pCAG-EGFP mice, shown by costaining with the muscle
membrane marker wheat germ agglutinin and DAPI. In the
brain, NeuN- (neurons) and GFAP-positive cells (astrocytes and
neural stem cells) are also EGFP-positive. DAB staining on
paraffin sections from liver, kidney, brain, lung and heart using
EGFP antibodies further confirmed these results (Figure S1). In
summary, the pCAG promoter offers very strong and ubiquitous
transgene expression in our modified Rosa26 locus. However, in
liver it shows a mosaic expression pattern (Figure 2C, Figure S1).
The EF1a promoter can be useful if moderate transgene levels are
required. The CMV promoter is not suitable for reliable transgene
expression from the modRosa26
LoxP locus, possibly due to
silencing effects that have been reported previously [40].
Tissue-specific promoters in the modRosa26
LoxP locus
We next tested whether tissue-specific promoters inserted into
the modRosa26
LoxP can be used to drive transgene expression in
defined cell types in vivo. In order to gain sensitivity in monitoring
promoter specificity, we generated mice using tissue-specific
promoters to drive the gene encoding for Cre recombinase. In
combination with an EGFP reporter system, we were able to
detect even low amounts of Cre expression throughout develop-
ment. Since the Cre/LoxP system is required for conditional
EGFP activation in ActB-EGFP reporter mice [15], we used
Flipase-mediated RMCE (Flp-RMCE) for rapid and efficient
targeting of the Rosa26 locus. Therefore, we generated the
modRosa26
FRT locus by introducing heterospecific FRT sites
(FRT3/FRTwt) in BALB/c ES cells in a manner analogous to that
described above for the modRosa26
LoxP locus (Figure 3A). The
resulting modRosa26
FRT ES cells were used for Flp-RMCE,
introducing the vascular endothelial cadherin (VeCad) [29] and
alpha smooth muscle actin (aSMA) [31] promoters driving Cre
(Figure 3B). The resulting mice (mR26-VeCad-Cre, mR26-
aSMA-Cre) were crossed with ActB-EGFP reporter mice [15],
and the double transgenic offspring (mR26-VeCad-Cre/ActB-
EGFP, mR26-aSMA-Cre/ActB-EGFP) were analyzed for EGFP
expression by immunohistochemistry. Immunostaining in mR26-
aSMA-Cre/ActB-EGFP mice using EGFP antibodies showed
specific staining of the smooth muscle cells in vessel and gut walls
in lung, stomach and intestine (Figure 3C). In addition, staining
was observed in cardiac muscle (data not shown), due to the
transient activity of the aSMA promoter in heart during
development [41]. However, few epithelial cells of the intestinal
villi were also EGFP positive, indicating rare ectopic aSMA
promoter activity (Figure 3C). In mR26-VeCad-Cre/ActB-EGFP
mice, EGFP staining was almost exclusively present in endothelial
cells, as seen in lung, brain and kidney while neighboring muscle
cells and other cell types were EGFP negative. However, few
EGFP positive epithelial cells in kidney also indicate ectopic
VeCad promoter activity (Figure 3C). Since low amounts of Cre
expression during development or in adult mice suffice to induce
EGFP expression in mR26-aSMA-Cre/ActB-EGFP or mR26-
VeCad-Cre/ActB-EGFP mice, our system is very sensitive for the
detection of nonspecific Cre expression. While aSMA and VeCad
promoters largely retained their specificity, two different Col1a1
promoters [42] used to drive Cre expression in our system entirely
lost their specificity, resulting in ubiquitous EGFP expression (data
not shown). Since tissue-specific activity of promoters targeted to
the modRosa26
FRT locus seems depend on the promoters used,
this approach requires careful characterization of the individual
models generated.
Combined Flp/FRT-mediated RMCE into a modified
Rosa26 locus (modRosa26
FRT) and Cre/LoxP-mediated
transgene activation
Another possibility to achieve tissue-specific transgene expression
is Cre/LoxP-mediated transgene activation using tissue-specific Cre
lines. In this system, a LoxP-flanked Stop cassette is placed between
the promoter and the transgene, which silences its transcription.
Tissue-specific Cre activity leads to the excision of the Stop cassette
and enables specific transgene expression. We have shown that the
pCAG promoter allows high transgene expression from the
modRosa26
LoxP locus after Cre-RMCE. Now, we combined Flp-
RMCE with Cre/LoxP conditional transgene activation. There-
fore, we performed Flp-RMCE into modRosa26
FRT ES cells,
introducing the pCAG promoter, a LoxP flanked Stop cassette [24]
and the EGFP reporter gene, which were then used to generate
mR26CS-EGFP mice. By crossing mR26CS-EGFP mice with
different Cre lines, tissue-specific and high EGFP expression can be
achieved (Figure 4A). We first crossed mR26CS-EGFP mice with
CMV-Cre full deleter mice [33], yielding mR26CD-EGFP/CMV-
Cre mice and Stop excision in all tissues and thus ubiquitous EGFP
expression in E12.5 embryos (Figure 4B). Next, Nestin-Cre mice
[34] were crossed with mR26CS-EGFP mice to activate EGFP
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EGFP/Nestin-Cre embryos (Figure 4B). E10.5 mR26CS-EGFP/
Myf5-Cre embryos resulting from mR26CS-EGFP mice crossed
with Myf5-Cre mice [43] show specific EGFP expression in the
somites, limbs and parts of the brain, as expected (Figure 4B). Single
transgenic mR26CS-EGFP mice showed no EGFP expression,
demonstrating that the Stop cassette efficiently shields the EGFP
gene from the pCAG promoter (Figure 4B).
Neural stem cells isolated from mR26CS-EGFP/Nestin-Cre
mice formed neurospheres and displayed high EGFP fluorescence,
allowing easy tracing of recombined cells without further staining.
Staining for GFAP and Tuj1 in differentiated neural stem cells
showed strong EGFP expression in both astrocytes (GFAP+) and
neurons (Tuj1+) (Figure 4C). In order to test conditional EGFP
expression in adult mR26CS-EGFP mice, we crossed them with
GlastCre-ER
T2 mice [36,37], allowing specific recombination
within astrocytes and the neural stem cell niche upon tamoxifen
injection. Tamoxifen-injected mR26CS-EGFP/GlastCre-ER
T2
mice showed strong and specific EGFP expression in the
subgranular zone of the dentate gyrus and the subventricular
zone, where the adult neural stem cells reside, and in astrocytes
(Figure 4D). Importantly, no staining for EGFP was required to
trace recombined cells. Our mR26CS-EGFP mice can therefore
serve as a reporter line to trace live recombined cells (e.g. for
Figure 2. Comparison of different ubiquitous promoters in the modRosa26
LoxP locus. (A) Organs from transgenic mice showing different
intensity of overall EGFP fluorescence under low-magnification microscopy, using the same conditions. ActB mice were used as controls for high
EGFP expression levels. The pCAG promoter shows the highest overall fluorescence. The CMV promoter showed strong activity only in testis. (B) EGFP
fluorescence was quantified in organ homogenates from mR26-pCAG-EGFP, mR26-EF1a-EGFP, mR26-CMV-EGFP and ActB mice. In most organs, EGFP
fluorescence was highest in mR26-pCAG-EGFP mice, except fat tissue where ActB mice showed higher levels. Heart, pancreas and muscle showed
extremely high levels of EGFP fluorescence. Background fluorescence determined in organ homogenates from wt mice was subtracted (n$3 mice per
genotype). Values are shown as mean 6 SEM. (C) Exemplary pictures from cryosections showing strong and ubiquitous EGFP expression in muscle
(costained with wheat germ agglutinin (WGA) for muscle fiber wall and DAPI) and brain (hippocampus, costained with NeuN for neurons and GFAP
for astrocytes). Mosaic EGFP fluorescence was detected in livers of mR26-pCAG-EGFP mice (costained with HNF4a for hepatocytes and DBA for bile
ducts). Magnified insets show both EGFP+ and EGFP- hepatocytes.
doi:10.1371/journal.pone.0030011.g002
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easily checked by analyzing tissue under a fluorescence microscope
after crossing them with mR26CS-EGFP mice.
To further improve detection of recombination events, monitor-
ing live animals would be desirable. For this purpose we performed
Flp-RMCE into modR26
FRT ES cells, introducing the pCAG
promoter, a LoxP-flanked Stop cassette and luciferase (Luc) [44]
cDNA (Figure 5A). Mice generated from positive recombined
mR26CS-Luc ES cells were crossed with CMV-Cre mice to induce
ubiquitous luciferase expression. Upon injection of Luciferin,
mR26CS-Luc/CMV-Cre mice were imaged using a Xenogen
camera and showed a strong luminescence signal throughout the
body, while no signal was observed in single transgenic mR26CS-
Luc control mice (Figure 5B). Next we crossed our mR26CS-Luc
mice with Albumin-Cre mice (Alb-Cre) [45], allowing liver-specific
luciferase expression. Tissue-specific luminescence was observed
after Luciferin injection in mR26CS-Luc/Alb-Cre mice, whereas
no signal was present in other tissue or in mR26CS-Luc controls
(Figure 5C). Thus, mR26CS-Luc could serve as a new reporter line
for rapid screening of newly generated Cre lines, since recombina-
tion events can be monitored easily in living mice.
Discussion
The aim of this study was to improve the generation of gain-of-
function ES cell lines and mouse models by facilitating the use of
exogenous promoters in the Rosa26 locus and accelerating the
generation of mutant ES cells using RMCE. We therefore
generated two ES cell lines with modified Rosa26 loci by intro-
ducing either heterospecific Lox511/LoxP sites (modRosa26
LoxP
ES cells) or FRT3/FRT sites (modRosa26
FRT ES cells). Mod-
Rosa26
LoxP ES cells allow for RMCE using the Cre/LoxP system,
while modRosa26
FRT ES cells can be used for RMCE using the
Flp/FRT system. All transgenic ES cell lines were successfully used
to generate highly chimeric transgenic mice that showed germline
transmission within the first litter. Compared to homologous
recombination, RMCE into the modRosa26 locus dramatically
increased the targeting efficacy and therefore minimizes time,
effort and costs for the generation of transgenic ES cells and mice
thereof. Most previous studies used the endogenous Rosa26
promoter to achieve ubiquitous gene expression in vitro and in vivo
at moderate levels [10,11,12,13]. However, the pCAG promoter
targeted to the Rosa26 locus offers 8- to 10-fold stronger transgene
Figure 3. Tissue-restricted gene expression from the modRosa26
FRT locus. A) Scheme depicting the generation of the modRosa26
FRT locus
in ES cells. A Stop sequence and a HygR selection cassette flanked by heterospecific FRT sites (FRT3 and FRTwt) were targeted to the Rosa26 locus
between exons 1 and 2 by homologous recombination. After successful recombination, the Stop cassette is located downstream of the endogenous
Rosa26 promoter (B) Flp-RMCE was performed by introducing the VeCad or aSMA promoter driving Cre recombinase into modRosa26
FRT ES cells,
which were then used to generate transgenic mice (mR26-VeCad-Cre or mR26-aSMA-Cre mice). The primers and probe for genotyping are indicated
(1–3). Both lines were crossed with ActB-EGFP reporter mice to monitor Cre expression, yielding mR26-VeCad-Cre/ActB-EGFP and mR26-aSMA-Cre/
ActB-EGFP mice. (C) Immunostaining for EGFP in mR26-aSMA-Cre/ActB-EGFP mice shows aSMA promoter activity almost exclusively in smooth
muscle cells, as seen in lung, stomach and intestine. Few EGFP stained intestinal epithelial cells indicate ectopic SMA promoter activity (asterisks) (D)
Immunostaining for EGFP in mR26-VeCad-Cre/ActB-EGFP mice reveals VeCad promoter activity mostly restricted to endothelial cells, as seen in lung,
brain and kidney. Some EGFP stained epithelial cells in kidney also indicate ectopic VeCad-Cre expression (asterisks).
doi:10.1371/journal.pone.0030011.g003
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other ubiquitous promoters or even tissue-specific promoters can
be used to drive transgene expression from the Rosa26 locus
remained elusive. Therefore, we decided to test several ubiquitous
and tissue-specific promoters in the modRosa26
LoxP locus in
combination with rapid ES cell targeting by RMCE. Although the
Figure 4. Generation of the modRosa26
FRT locus and a reporter strain for strong EGFP expression. (A) Flp-RMCE into the modRosa26
FRT
locus, replacing the HygR selection cassette in the modRosa26
FRT ES cells with an FRT/FRTwt-flanked sequence in the Flp-RMCE targeting plasmid.
The Flp-RMCE targeting plasmid contains the pCAG promoter followed by a LoxP-flanked (floxed) STOP cassette, the EGFP cDNA and a NeoR cassette,
flanked as a group by FRT/FRTwt sites. Successfully targeted ES cells were used to generate mR26-CS-EGFP mice. After crossing mR26-CS-EGFP mice
with several Cre mice, ubiquitous or tissue-restricted EGFP reporter expression could be obtained. (B) mR26CS-EGFP/CMV-Cre E12.5 embryos show
ubiquitous EGFP expression, while mR26CS-EGFP/Nestin-Cre mice show EGFP expression restricted to the brain and neural tube. EGFP expression in
E10.5 mR26CS-EGFP/Myf5-Cre embryos was restricted to the somites (magnified inset), limbs and parts of the brain. (C) Neural stem cells isolated
from E14.5 mR26CS-EGFP/Nestin-Cre mice form neurospheres with ubiquitous and strong EGFP fluorescence, while mR26CS-EGFP mice show no
fluorescence. These cells were subsequently differentiated (lower panels), showing strong EGFP fluorescence in mR26CS-EGFP/Nestin-Cre-derived
cells (counterstained with DAPI, the neuronal marker Tuj1 and the glial marker GFAP). (D) Adult mR26CS-EGFP/Glast-CreERT2 mice show strong and
specific EGFP fluorescence in astrocytes and in the adult neural stem cell niche (asterisks) upon tamoxifen administration. EGFP+ adult neural stem
cells are present in the subgranular zone (SGZ) of the dentate gyrus and the subventricular zone (SVZ). Recombined EGFP+ cells from the SVZ can be
traced through the rostral migratory stream into the olfactory bulb. NeuN stains for mature neurons (blue) and BLBP for adult neural stem cells and
astrocytes (red). Note: no EGFP-antibody staining was used in C–E, since the mR26CS-EGFP reporter mouse offers very high EGFP expression levels
which can be easily detected without any staining.
doi:10.1371/journal.pone.0030011.g004
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FRT locus was performed, replacing the
HygR in the modRosa26
FRT ES cells with the FRT/FRTwt-flanked sequence from the Flp-RMCE targeting plasmid. The Flp-RMCE targeting plasmid
contains the pCAG promoter followed by a LoxP-flanked (floxed) STOP cassette (STOP2), the luciferase cDNA and a NeoR cassette, flanked as a group
by FRT3/FRTwt sites. Successfully targeted ES cells were used to generate mR26CS-Luc mice. After crossing mR26CS-Luc mice with Cre mice,
ubiquitous or tissue-restricted luciferase reporter expression can be obtained to monitor reporter expression in living mice upon Luciferin injection.
Using Xenogen imaging, adult mR26CS-Luc/CMV-Cre mice show ubiquitous luciferase activity throughout the body (B), while mR26CS-Luc/AlbCre
mice show luciferase activity restricted to the liver upon Luciferin injection (C). Luciferin-injected mR26SC-Luc control mice never showed luciferase
activity.
doi:10.1371/journal.pone.0030011.g005
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comparable transgene expression in vitro in ES cells, only the
pCAG promoter induced high transgene levels in vivo in the
modRosa26
LoxP locus. In contrast to the pCAG and EF1a
promoters, the CMV promoter was not active in most tissues in
vivo, consistent with other studies showing that the CMV promoter
is susceptible to silencing effects in transgenic mice [40]. It is
possible that the NeoR cassette interferes with the transgene
expression, depending on the promoter used.
When targeted to the Rosa26 locus without shielding the
Rosa26 promoter, the pCAG promoter showed mosaic expression
in skeletal muscle, lung and liver [14]. Since it was suggested that
the Rosa26 promoter can influence the expression of inserted
transgenes [14,17], we introduced a Stop cassette downstream of
the Rosa26 sense promoter to shield our expression cassette.
Indeed, transgenic ES cells with this modification showed no
EGFP expression in vitro when no exogenous promoter was
inserted, indicating that the Rosa26 promoter was functionally
silenced. In the modRosa26
LoxP locus, the pCAG promoter
showed strong and ubiquitous EGFP expression in skeletal muscle
and other organs analyzed. Only in the liver the EGFP expression
remained mosaic, showing a clear improvement to previous pCAG
driven transgene expression from the Rosa26 locus [14]. Possibly,
removing the NeoR cassette or improved shielding of the Rosa26
promoter elements could further improve ubiquitous transgene
expression using the pCAG promoter targeted to the Rosa26
locus. A clear advantage of the pCAG promoter is that it yields
very high expression levels. Thus, pCAG promoter mice enable
tracing of live cells for differentiation studies, electrophysiology
and intravital microscopy in which recombination events need to
be monitored by direct EGFP fluorescence. This is in contrast to
the endogenous, ubiquitously active Rosa26 promoter that results
in low and often insufficient levels of transgene expression that is
not detectable without further immunostaining [12,13,46].
UsingCrerecombinaseasa sensitivereporterthat wasmonitored
by ActB-EGFP reporter mice [15], we analysed specificity tissue-
specific promoters in the modRosa26 locus. Although aSMA and
VeCad promoters mostly retained their specificity in vivo when
targeted to the modRosa26 locus, rare ectopic transgene expression
was observed. Col1a1 promoters entirely lost the tissue-specificity,
resulting in ubiquitous transgene expression. Although we could
show that the endogenous Rosa26 promoter was functionally
silenced in the modRosa26 locus, it is possible that inserted tissue-
specific promoters lose specificity due to positional influences.
Therefore, using the modRosa26 locus in combination with tissue-
specific promoters driving Cre requires careful characterization.
However, unspecific or mosaic Cre expression is a general problem
when using isolated promoter constructs and can often only be
circumvented by a knock-in of Cre into the endogenous gene locus.
When high amounts of non-conditional transgene expression from
tissue-specific promoters are required, classical transgenic mice with
multiple transgene insertions are still inevitable despite all their
disadvantages, as mentioned above.
In order to facilitate high level transgene expression in a tissue-
specificmanneralongwith theadvantagesofsingle-copyintegration
into a defined locus, we now generated the modRosa26
FRT locus.
We combined Flp/FRT-mediated RMCE into the modRosa26
FRT
locus with conditional Cre/LoxP-mediated transgene expression
from the pCAG promoter. This approach allows for reliable high-
level transgene expression in the desired tissue using established Cre
lines. Using this approach we generated two reporter mouse lines.
The great advantage of mR26CS-EGFP reporter mice is the high
EGFP fluorescence that allows monitoring of recombination events
in live cells. Going one step further, mR26CS-Luc reporter mice
even allow monitoring of recombination events in live animals upon
luciferase injection. In particular, this allows initial screening of new
Cre lines without extensive histological analysis, since promising
candidates can be selected very rapidly by Xenoimaging. In
addition, these mice could be used to monitor tumor formation in
combination with Cre/LoxP conditional deletion of tumor
suppressors or activation of oncogenes.
In summary, we modified the Rosa26 locus to facilitate the use
of exogenous promoters and to accelerate the generation of
transgenic ES cells and transgenic mice for gain-of-function
studies. We characterized several ubiquitous and tissue-specific
promoters in vivo. Using tissue-specific promoters for low-level
transgene expression or combined Flp-RMCE and Cre/LoxP
conditional transgene expression for high-level expression, we
accelerated the generation of single-copy transgenic mice targeted
to a defined locus as an alternative to classical transgenic mice
produced by pronuclear microinjections. When well-characterized
Cre lines are available for the tissue of interest, we believe that our
system is preferable to classical transgenic mice, since it offers
reliable and predictable expression profiles and rapid generation
and therefore minimized costs and effort.
Supporting Information
Figure S1 Immunohistochemistry for EGFP in mR26-
pCAG-EGFP mice. DAB staining for EGFP on paraffin sections
from mR26-pCAG-EGFP mice show ubiquitous EGFP expression
in kidney, brain, heart and lung. For the brain, exemplary sections
of cerebellum and the hippocampal CA1 region are shown. The
liver shows broad EGFP staining in liver arteries and bile ducts,
but mosaic staining in hepatocytes. EGFP-negative hepatocytes
are indicated by asterisks.
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